|
Chongkundang is a pharmaceutical company established in 1941 that develops, manufactures, and markets prescription and over-the-counter medicines. The company's portfolio includes proprietary drugs, improved new drugs, generics, and biosimilars, with key products including the anticancer agent Camto, the diabetes treatment Duvie, the natural medicine Jitec, and the biosimilars Nesvel and Lucenvis. It maintains active research and development programs in targeted cancer therapies, antibody-drug conjugates, and gene therapy, and has entered into a technology licensing agreement with Novartis for the HDAC6 inhibitor CKD-510. Chongkundang serves domestic and international markets, including Japan, Vietnam, and Indonesia, through its own distribution networks and partnerships. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage ckdpharm.com |
| Sector Healthcare | IR page — | |
|
Tags
prescription drugs, over-the-counter drugs, biosimilars, oncology, diabetes, antibody-drug conjugates, gene therapy, natural medicines, hdac6 inhibitors, Camto, Duvie, Jitec, Nesvel, Lucenvis, CKD-510, CKD-702, CKD-703, CKD-704, CKD-706, CKD-508, CKD-512, CKD-11101, CKD-701, CKD-943, CKD-950, CKD-951, CKD-920, CKD-101, Penzal, Prepmin, Eaton Q, Sokcheong, Gliatin, Dilatren, Zanuvia, Zanumet, Steglujan, Stelattro, Nexavar, Stivarga, Wegovy, Verkuvo, Eylea, Pexula, Adalat Oros, Aspirin Protect, Neurapec, Braining, Karendia, Boreng Flu V Tetra, Bio Spike Guard, Godeks, MIND STIM+, Prevena 20, Tedopi, Namodenoson, IFN-K, Lobeglitazone, Senvido
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 1.224T |
| Market cap (USD) | $ 900.926M |
| P/E | 14.71 |
| PEG | — |
| P/BV | 1.21 |
| P/S | 0.69 |
| P/OCF | 9.93 |
| P/FCF | -18.71 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 8.2% |
| ROI | 7.7% |
| ROIC | 7.7% |
| Profit margin | 4.6% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -1.4% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.692T | 1.586T | 1.669T | 1.488T | 1.344T | 1.303T | 1.079T | 956.219B | 884.363B | 831.986B | 592.493B | 544.13B | 86.318B |
| Net profit | 77.509B | 109.073B | 212.521B | 80.953B | 42.72B | 91.633B | 53.882B | 42.399B | 53.807B | 40.946B | -6.773B | 35.154B | 4.417B |
| Free cash flow | -73.558B | 25.815B | 276.942B | 22.836B | -35.339B | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 197B | 192B | 191B | 174B | 183B | 204B | 248B | 270B | 267B | 266B |
| ↳ YoY growth | +18.6% | -2.1% | -0.7% | -8.9% | +5.3% | +11.1% | +22.0% | +8.5% | -1.1% | -0.3% |
| ↳ 5y CAGR | +2.0% | +0.7% | +5.2% | +7.1% | +8.9% | +7.7% | ||||
| Other receivables (KRW) | 12.9B | 17.5B | 16.7B | 23.3B | 35.8B | 24.6B | 30.9B | 39.4B | — | — |
| Borrowings, current (KRW) | 84.6B | 81.1B | 58.6B | 89.5B | 76B | 99.3B | 124B | 182B | 66.5B | 163B |
| Borrowings, non-current (KRW) | 40B | 21.4B | 45.9B | 21.5B | 55B | 134B | 111B | 30B | 116B | 195B |
| Lease liabilities (KRW) | — | — | — | 7.01B | 5.16B | 3.47B | 1.69B | 8.06B | 5.7B | 9.73B |
| Cash and deposits (KRW) | 21.7B | 45.5B | 45.9B | 76.9B | 124B | 132B | 117B | 220B | 228B | 216B |
| Intangible assets (KRW) | 14.9B | 14.3B | 15.4B | 15.9B | 19B | 20.8B | 27B | 52.5B | 75.6B | 108B |
| Right-of-use assets (KRW) | — | — | — | 6.92B | 5.04B | 3.36B | 1.66B | 7.9B | 5.48B | 9.56B |
| Net debt (borrowings + leases - cash) (KRW) | 18.3B | 57B | 58.5B | 41.1B | 12.5B | 105B | 118B | 118M | -40.3B | 152B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 57.8B | 81.7B | 42.6B | 77.3B | 104B | 12.9B | 67.7B | 318B | 64.3B | 67.4B |
| Purchases of property, plant and equipment (KRW) | — | — | — | — | — | -48.2B | -44.9B | -41.2B | -38.5B | -141B |
| Purchases of intangible assets (KRW) | — | — | — | — | — | -3.6B | -8.17B | -27.6B | -27.6B | -38.2B |
| Dividends paid (cash effect) (KRW) | — | — | — | — | — | -10.8B | -11.2B | -11.6B | -13.3B | -13.8B |
| Share buybacks (cash effect) (KRW) | — | — | — | — | — | — | -1.89B | -6.02B | -16B | -1.77B |
| Interest paid (cash effect) (KRW) | -4.17B | -3.54B | -2.78B | -2.94B | -3.64B | -3.76B | -6.44B | -8.63B | -7.65B | -6.23B |
| Income taxes paid (cash effect) (KRW) | -12.7B | -19B | -27.5B | -22B | -18.3B | -51.7B | -15.6B | -11.8B | -34.9B | -23.8B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | — | — | — | — | — | -38.9B | 14.7B | 249B | -1.81B | -112B |
| Income detail | ||||||||||
| Research and development expense (KRW) | — | — | — | — | — | 163B | 176B | 140B | 144B | 154B |
| Total comprehensive income (KRW) | 45.3B | 55.7B | 40.1B | 53.3B | 88.7B | 38.7B | 84.5B | 212B | 110B | 118B |
| Comprehensive income to owners (KRW) | 45.3B | 55.9B | 40.8B | 54.1B | 89.9B | 39B | 85.4B | 211B | 108B | 118B |
| Reported | Apr 2, 2018 | Apr 2, 2018 | Apr 1, 2019 | Mar 30, 2020 | Mar 18, 2021 | Mar 20, 2024 | Mar 25, 2025 | Mar 25, 2025 | Mar 25, 2025 | Mar 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
2026-11-05
2026-11-05
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding CHONGKUNDANG
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.04% | 1,018 | $ 46.478K | Nov 16, 2026 |
| AVEM | 0.01% | 29,512 | $ 1.347M | Nov 16, 2026 |
| AVES | 0.01% | 2,099 | $ 95.832K | Nov 16, 2026 |
| DFEV | 0.01% | 3,932 | $ 190.918K | Nov 12, 2026 |
| DFSE | 0.01% | 857 | $ 41.612K | Nov 12, 2026 |
| DFEM | 0.01% | 9,687 | $ 470.352K | Nov 12, 2026 |
| DEXC | 0.01% | 275 | $ 13.353K | Nov 12, 2026 |
| DFAE | 0.00% | 6,673 | $ 324.008K | Nov 12, 2026 |
| DFAX | 0.00% | 5,980 | $ 290.359K | Nov 12, 2026 |
| AVXC | 0.00% | 240 | $ 10.958K | Nov 16, 2026 |